ERBB2 and breast cancer: Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+endocrine therapy in patients with HR+, HER2− early BC at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).